Literature DB >> 33397681

Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.

Ravindra Uppaluri, Katie M Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L Skidmore, Brian Nussenbaum, Randal C Paniello, Jason T Rich, Ryan Jackson, Patrik Pipkorn, Loren S Michel, Jessica Ley, Peter Oppelt, Gavin P Dunn, Erica K Barnell, Nicholas C Spies, Tianxiang Lin, Tiantian Li, David T Mulder, Youstina Hanna, Iulia Cirlan, Trevor J Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Y Jo, Matthew D Stachler, Glenn J Hanna, Jason Kass, Robert Haddad, Jonathan D Schoenfeld, Evisa Gjini, Ana Lako, Wade Thorstad, Hiram A Gay, Mackenzie Daly, Scott J Rodig, Ian S Hagemann, Dorina Kallogjeri, Jay F Piccirillo, Rebecca D Chernock, Malachi Griffith, Obi L Griffith, Douglas R Adkins.   

Abstract

Entities:  

Year:  2021        PMID： 33397681     DOI： 10.1158/1078-0432.CCR-20-4484

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  2 in total

1.  Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.

Authors:  Trisha M Wise-Draper; Shuchi Gulati; Sarah Palackdharry; Benjamin H Hinrichs; Francis P Worden; Matthew O Old; Neal E Dunlap; John M Kaczmar; Yash Patil; Muhammed Kashif Riaz; Alice Tang; Jonathan Mark; Chad Zender; Ann M Gillenwater; Diana Bell; Nicky Kurtzweil; Maria Mathews; Casey L Allen; Michelle L Mierzwa; Keith Casper; Roman Jandarov; Mario Medvedovic; J Jack Lee; Nusrat Harun; Vinita Takiar; Maura Gillison
Journal:  Clin Cancer Res       Date:  2022-04-01       Impact factor: 13.801

2.  Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response.

Authors:  Manuel Olmos; Jacek Glajzer; Tjark-Ole Büntemeyer; Gesche Frohwitter; Jutta Ries; Markus Eckstein; Markus Hecht; Rainer Lutz; Marco Rainer Kesting; Manuel Weber
Journal:  Front Oncol       Date:  2021-07-21       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.